(Circulation. 2000;102:1883.)
© 2000 American Heart Association, Inc.
Brief Rapid Communications |
Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders
From the Institut de cardiologie de Québec, Hôpital Laval
(B.D., P.D., J.T.) et Facultés de Pharmacie (B.D., J.T.) et de
Médecine (P.D.), Université Laval, Sainte-Foy, Québec,
Canada, and the Centre de Recherche, Hôpital du Sacré-C
ur
de Montréal (G.R., R.C., J.T.), Département de Pharmacologie,
Faculté de Médecine (G.R., R.C., J.T.) et Faculté de
Pharmacie (J.T.), Université de Montréal, Montréal,
Québec, Canada.
Correspondence to Jacques Turgeon, PhD, Dean, Faculty of Pharmacy, University of Montreal, CP 6128 succursale Centre-ville, Montreal QC Canada H3C 3J7. E-mail jacques.turgeon{at}umontreal.ca
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Several cases of QT prolongation and ventricular tachyarrhythmia have been reported with domperidone, a gastrokinetic and antiemetic agent available worldwide but still under investigation in the United States. Although electrolyte disturbances such as hypokalemia could account for some of these events, we hypothesized that domperidone may have unsuspected electrophysiological effects predisposing some patients to proarrhythmia.
Methods and Results—Studies were undertaken in 9 isolated guinea pig hearts, which demonstrated reverse use–dependent prolongation of cardiac repolarization by 100 nmol/L domperidone. Action potential duration increased 27% from baseline with domperidone (from 114±3 to 145±2 ms) during pacing at a cycle length of 250 ms, and a 9% increase (from 97±2 to 106±3 ms) was seen with pacing at a cycle length of 150 ms. Experiments in human ether-a-go-go–related gene (HERG)-transfected Chinese hamster ovary cells (n=32) demonstrated a concentration-dependent block of the rapid component (IKr) of the delayed rectifier potassium current. The tail current decreased by 50% at 162 nmol/L domperidone.
Conclusions—Domperidone possesses cardiac electrophysiological effects similar to those of cisapride and class III antiarrhythmic drugs. These effects are observed at clinically relevant concentrations of the drug. Therefore, domperidone should not be considered a no-risk alternative to cisapride, a drug that was recently withdrawn from the US market.
Key Words: arrhythmia • ion channels • torsade de pointes • electrophysiology • long-QT syndrome
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Domperidone (Motilium) has been marketed worldwide since 1978, but it is still under investigation in the United States. It is a unique compound that has both gastrokinetic and antiemetic activities. Chemically distinct from cisapride, domperidone is a peripheral dopamine2-receptor antagonist that might seem to be an attractive, safer alternative to cisapride, a drug that was recently withdrawn from the US market due to drug-related proarrhythmic events.1 2 3
However, QT prolongation, life-threatening ventricular tachyarrhythmias, and even cardiac arrests have also been reported after the use of domperidone.4 5 6 7 8 9 10 11 It was generally assumed that these adverse effects were related to an underlying electrolytic disturbance, eg, hypokalemia, and not to a specific drug effect.5 7 8 9
We investigated whether unexpected electrophysiological effects of domperidone on cardiac repolarization might also provide an explanation for some of the observed proarrhythmic events. Therefore, we determined the action potential–prolonging effects of domperidone in isolated hearts and characterized the effects of the drug on a major cardiac potassium current (IKr) using the whole-cell patch-clamp technique.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Experiments were performed in accordance with our institutional guidelines on animal use in research. Animals were housed and maintained in compliance with the Guide to the Care and Use of Experimental Animals of the Canadian Council on Animal Care.
Experiments With Isolated Hearts
Experiments with isolated guinea pig hearts were performed as
described previously.12 The hearts were perfused with
Krebs-Henseleit buffer during a control period of 10 minutes; this was
followed by 15 minutes of perfusion with buffer containing 100 nmol/L
domperidone dissolved in 1 mL of DMSO. Perfusion with buffer
containing no drug was then restarted during a 10-minute washout
period. The same concentration of DMSO (0.1% v/v) was also present
in baseline and washout buffer solutions. Monophasic action potentials
from the left ventricle were recorded by a pressure-maintained
catheter every 60 s for a 3-s period at basic pacing cycle
lengths (BCL) of 250, 200, and 150 ms.
Patch-Clamp Experiments
Experiments were performed on HERG-transfected Chinese hamster
ovary (CHO) cells. Preparation and harvesting of the CHO cells were
done as described previously.13 Membrane currents were
recorded in whole cell configuration using suction pipettes. The
composition of the superfusion and internal pipette solutions was also
described previously.14 Domperidone solutions of 30 nmol/L
to 1 µmol/L were prepared daily by dissolving the required
amounts of the drug in 100 µL of DMSO. The same concentration of DMSO
(0.1% v/v) was also present in baseline and washout buffer
solutions. All voltage-clamp experiments were performed at 22°C to
23°C.
Statistical Analysis
Data are presented as mean±SEM. The magnitude of
domperidone effects for isolated heart data were analyzed with
Student’s paired t test. In the patch-clamp experiments,
the concentration-dependent block of the HERG tail current was tested
by Hotelling’s T2-test.
P<0.05 was considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Experiments With Isolated Hearts
Examples of monophasic action potentials recorded at baseline and during perfusion with 100 nmol/L domperidone at a BCL of 250 ms are illustrated in Figure 1A
.
Experiments in isolated hearts (n=9) showed an increase in monophasic
action potential duration measured at 90% repolarization
(MAPD90) during perfusion with domperidone
(Figure 1B). At a BCL of 250 ms, MAPD90
increased from 114±3 ms at baseline to 145±2 ms after 15 minutes of
drug perfusion (P<0.05); it then decreased back to 136±2
ms after 10 minutes of washout (P<0.05 versus domperidone).
At a BCL of 200 ms, MAPD90 increased from 110±2
ms at baseline to 130±3 ms after 15 minutes of drug perfusion
(P<0.05); it decreased back to 118±3 ms after 10 minutes
of washout (P<0.05 versus domperidone). Finally, at the
shortest BCL of 150 ms, MAPD90 increased from
97±2 at baseline to 106±3 ms after domperidone perfusion
(P<0.05), and it returned to baseline levels after washout
(99±4 ms). Thus, domperidone was associated with a 27% increase in
MAPD90 at the longest BCL and with a 9% increase
at the shortest BCL. Such reverse use–dependent characteristics are
typically seen with IKr blockers.
|
Patch-Clamp Experiments
The mechanism underlying the action potential–prolonging
effects of domperidone was investigated by conducting patch-clamp
experiments in CHO cells. Figure 2A shows
the currents elicited in a HERG-transfected CHO cell perfused under
control conditions (baseline), after 15 minutes of 300 nmol/L
domperidone, and after a 20-minute washout period. In this cell, 300
nmol/L domperidone caused a 59% reduction of the tail current. Similar
experiments were conducted in a total of 32 cells (n=8/concentration).
The block of tail currents was assessed with domperidone concentrations
ranging from 30 nmol/L to 1 µmol/L, and the data were fitted to
the Hill equation, which gave an estimated IC50
of 162 nmol/L (Figure 2B). The decrease in the tail current was
12±6% at 30 nmol/L, 35±4% at 100 nmol/L, 65±4% at 300 nmol/L, and
95±1% at 1 µmol/L.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Our results indicate that domperidone can prolong cardiac repolarization in a reverse rate–dependent manner by blocking IKr. In fact, we showed that 100 nmol/L domperidone caused a significant prolongation of cardiac repolarization (
25% to 30%). Excessive IKr block may lead
to triggered tachyarrhythmias and sudden
death.15 These results provide a new explanation for QT
prolongation and ventricular
tachyarrhythmia during domperidone treatment. An inhibition of the HERG current was demonstrated in CHO cells. The estimated IC50 for IKr was 162 nmol/L. Pharmacokinetic studies showed that the mean plasma concentration of domperidone in healthy subjects is 21 ng/mL (49 nmol/L) after 14 days of domperidone at a dose of 30 mg/d, which was similar to the mean plasma concentration of 18 ng/mL (42 nmol/L) observed after the first dose.16 However, the mean maximal concentration values achieved 30 minutes after 10 and 60 mg oral doses of domperidone were 23 and 80 ng/mL (54 and 188 nmol/L), respectively.17 Therefore, a reduction of the IKr current and delayed cardiac repolarization are expected to be seen in patients treated with the recommended doses of domperidone (10 to 20 mg TID/QID).
Similar electrophysiological properties have been extensively described recently with cisapride, another gastrokinetic drug. This drug had to be withdrawn from the US market due to unacceptable cardiac toxicity.2 3 12 Because cisapride was one of the overall most-prescribed drugs in the United States and definitely the most prescribed in its therapeutic class, its withdrawn will cause a rapid shift toward alternative therapies.
With both gastrokinetic and antiemetic activities, domperidone provides short-term relief of dyspepsia, diabetic gastroparesis, or gastroesophageal reflux, and it prevents the nausea and vomiting associated with chemotherapy and antiparkinsonian drugs.1
Unlike metoclopramide, another prokinetic dopamine-receptor antagonist, domperidone does not readily cross the blood-brain barrier, and reports of adverse effects on the central nervous system, such as dystonic reactions, are rare.1 Moreover, in the management of diabetic gastropathy, domperidone’s antiemetic activity distinguishes it from cisapride.
Because of its "apparent" favorable safety profile, domperidone might seem to be an appealing, safer alternative to cisapride. In view of the present findings and considering previous reports on domperidone cardiac toxicity,4 5 6 7 8 9 10 11 this should not be the case. Clinical attention should be directed toward QT prolongation and proarrhythmic events when domperidone is administered, as it was with cisapride. Because domperidone can block IKr, caution is also needed during coadministration with other IKr blockers, like class III drugs and other compounds such as antimicrobials, antihistamines, and neuroleptics.18 19 20 21 Domperidone should be one of the next compounds to add to the growing list of drugs associated with acquired long-QT syndrome.
Conclusions
Domperidone is a potent IKr blocker. It
prolongs cardiac repolarization at clinically relevant drug
concentrations, and it should not be considered a no-risk alternative
to cisapride. Therefore, clinical attention to QT prolongation and
triggered ventricular tachyarrhythmias
should be warranted when prescribing domperidone, particularly in
patients with hepatic or renal insufficiency, in those who suffer from
long-QT syndrome, and in patients on multidrug regimens.
|
Acknowledgments |
|---|
This study was supported by the Medical Research Council of Canada (grant MT-11876) and the Heart and Stroke Foundation of Quebec. B. Drolet is the recipient of studentships from the Heart and Stroke Foundation of Canada and from the Fonds pour la Formation de Chercheurs et l’Aide à la Recherche (FCAR). Dr Rousseau is the recipient of a scholarship from the MRC/Canadian Hypertension Society. Dr Daleau is the recipient of a scholarship from the Fonds de la Recherche en Santé du Québec (FRSQ). Dr Turgeon was the recipient of a scholarship from the Joseph C. Edwards Foundation. The authors also thank Michel Blouin, Lynn Atton, and Chantal de Montigny for technical assistance.
Received June 23, 2000; revision received August 22, 2000; accepted August 23, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33:429–440.[Abstract]
2.
Bran S, Murray WA, Hirsch IB, et al. Long QT
syndrome during high-dose cisapride. Arch Intern Med. 1995;155:765–768.
3. Lewin MB, Bryant RM, Fenrich AL, et al. Cisapride-induced long QT interval. J Pediatr. 1996;128:279–281.[Medline] [Order article via Infotrieve]
4. Bruera E, Villamayor R, Roca E, et al. QT interval prolongation and ventricular fibrillation with i.v. domperidone. Cancer Treat Rep. 1986;70:545–546.[Medline] [Order article via Infotrieve]
5. Osborne RJ, Slevin ML, Hunter RW, et al. Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Hum Toxicol. 1985;4:617–626.[Medline] [Order article via Infotrieve]
6.
Cameron HA, Reyntjens AJ, Lake-Bakaar G, et al.
Cardiac arrest after treatment with intravenous
domperidone. BMJ. 1985;290:160. Letter.
7. Quinn N, Parkes D, Jackson G, et al. Cardiotoxicity of domperidone. Lancet. 1985;2:724. Letter.
8. Osborne RJ, Slevin ML, Hunter RW, et al. Cardiotoxicity of intravenous domperidone. Lancet. 1985;2:385. Letter.
9. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. BMJ. 1984;289:1579. Letter.
10. Giaccone G, Berletto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet. 1984;2:1336–1337.
11. Joss RA, Goldhirsch A, Brunner KW, et al. Sudden death in a cancer patient on high dose domperidone. Lancet. 1982;1:1019.
12.
Drolet B, Khalifa M, Daleau P, et al. Block of
the rapid component of the delayed rectifier potassium current by the
prokinetic agent cisapride underlies drug-related lengthening of the QT
interval. Circulation. 1998;97:204–210.
13. Bérubé J, Chahine M, Daleau P. Modulation of HERG potassium channel properties by external pH. Pflügers Arch. 1999;438:419–422.[Medline] [Order article via Infotrieve]
14. Zhou Z, Gong Q, Ye B, et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J. 1998;74:230–241.[Medline] [Order article via Infotrieve]
15. Priori SG. Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol. 1998;9:1114–1116.[Medline] [Order article via Infotrieve]
16. Huizing G, Brouwers JRBJ, Westhuis P. Plasma drug concentration and prolactin release after acute and subchronic oral administration of domperidone and metoclopramide. In: Merkus F, ed. The Serum Concentration of Drugs. Amsterdam: Excerpta Medica; 1980:271–277.
17. Heykants J, Hendriks R, Meuldermans W, et al. On the pharmacokinetics of domperidone in animals and man, IV: the pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6:61–70.[Medline] [Order article via Infotrieve]
18.
Daleau P, Lessard E, Groleau MF, et al.
Erythromycin blocks the rapid component of the delayed rectifier
potassium current and lengthens repolarization of guinea pig
ventricular myocytes. Circulation. 1995;91:3010–3016.
19.
Khalifa M, Drolet B, Daleau P, et al. Block of
potassium currents in guinea pig ventricular myocytes and
lengthening of cardiac repolarization in man by the histamine
H1-receptor antagonist diphenhydramine. J
Pharmacol Exp Ther. 1999;288:858–865.
20.
Drolet B, Vincent F, Rail J, et al. Thioridazine
lengthens repolarization of cardiac ventricular myocytes by
blocking the delayed rectifier potassium current. J
Pharmacol Exp Ther. 1999;288:1261–1268.
21. Drolet B, Zhang S, Deschênes D, et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol. 1999;10:1597–1604.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  R. Hreiche, P. Morissette, H. Zakrzewski-Jakubiak, and J. Turgeon Gender-related Differences in Drug-induced Prolongation of Cardiac Repolarization in Prepubertal Guinea Pigs Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2009; 14(1): 28 - 37. [Abstract] [PDF]
|
|
|
|
 |
|
 C. A. Bryant Nursing the adopted infant. J Am Board Fam Med, July 1, 2006; 19(4): 374 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. S. Li, C. Schmauss, A. Cuenca, E. Ratcliffe, and M. D. Gershon Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J. Neurosci., March 8, 2006; 26(10): 2798 - 2807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M.J.M. Straus, M. C.J.M. Sturkenboom, G. S. Bleumink, J. P. Dieleman, J. v. d. Lei, P. A. d. Graeff, J. H. Kingma, and B. H.Ch. Stricker Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death Eur. Heart J., October 1, 2005; 26(19): 2007 - 2012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G A Fontana and M Pistolesi Cough {middle dot} 3: Chronic cough and gastro-oesophageal reflux Thorax, December 1, 2003; 58(12): 1092 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Desta, G. M. Wu, A. M. Morocho, and D. A. Flockhart The Gastroprokinetic and Antiemetic Drug Metoclopramide Is a Substrate and Inhibitor of Cytochrome P450 2D6 Drug Metab. Dispos., March 1, 2002; 30(3): 336 - 343. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||